PDF(Pubmed)
Abstract：
UNASSIGNED: Andrographis paniculata (Burm.f.) Nees has been recommended to relieve symptoms and decrease the severity of COVID-19. The clinical study aimed to investigate the efficacy and safety of A. paniculata ethanolic extract (APE).
UNASSIGNED: The efficacy and safety of APE in asymptomatic or mildly symptomatic COVID-19 patients compared with placebo were investigated through a prospective, double-blind randomized control trial. Patients received APE containing 60 mg of andrographolide, three times a day for five days. WHO progression scale, COVID-19 symptoms, and global assessment evaluated the efficacy and adverse events, liver and renal functions were monitored for safety.
UNASSIGNED: 165 patients completed the study (83 patients in the APE group and 82 patients in the placebo group). The highest WHO progression scale was 4 and COVID-19 symptoms were significantly relieved on the last day of intervention in both groups, with no significant difference between groups. APE significantly relieved headache symptoms on day 1 and olfactory loss symptoms on day 2 compared to placebo. The global assessment showed that 80.7% of patients had total recovery after 5-day treatment with APE. Mild diarrhea was the most common side effect with a high dose that resolved within a few days. No hepatic or renal toxicity was associated with treatment.
UNASSIGNED: APE at 180 mg/day for 5 days did not reduce COVID-19 progression in asymptomatic or mildly afflicted COVID-19 patients, however, it shortened the symptoms of olfactory loss with no adverse effects over 5 days of use.
UNASSIGNED: The efficacy and safety of APE in asymptomatic or mildly symptomatic COVID-19 patients compared with placebo were investigated through a prospective, double-blind randomized control trial. Patients received APE containing 60 mg of andrographolide, three times a day for five days. WHO progression scale, COVID-19 symptoms, and global assessment evaluated the efficacy and adverse events, liver and renal functions were monitored for safety.
UNASSIGNED: 165 patients completed the study (83 patients in the APE group and 82 patients in the placebo group). The highest WHO progression scale was 4 and COVID-19 symptoms were significantly relieved on the last day of intervention in both groups, with no significant difference between groups. APE significantly relieved headache symptoms on day 1 and olfactory loss symptoms on day 2 compared to placebo. The global assessment showed that 80.7% of patients had total recovery after 5-day treatment with APE. Mild diarrhea was the most common side effect with a high dose that resolved within a few days. No hepatic or renal toxicity was associated with treatment.
UNASSIGNED: APE at 180 mg/day for 5 days did not reduce COVID-19 progression in asymptomatic or mildly afflicted COVID-19 patients, however, it shortened the symptoms of olfactory loss with no adverse effects over 5 days of use.
摘要：
■穿心莲（Burm.f.）Nees被建议缓解症状并降低COVID-19的严重程度。本研究旨在探讨紫菜乙醇提取物(APE)的有效性和安全性。
■通过前瞻性研究，与安慰剂相比，APE在无症状或轻度症状COVID-19患者中的疗效和安全性，双盲随机对照试验。患者接受含有60毫克穿心莲内酯的APE，一天三次，五天。世卫组织进展量表，COVID-19症状，和全球评估评估的疗效和不良事件，监测肝肾功能的安全性.
■165名患者完成了研究（APE组83名患者，安慰剂组82名患者）。WHO进展评分最高为4分，两组在干预的最后一天COVID-19症状均明显缓解，组间无显著差异。与安慰剂相比，APE在第1天显著缓解头痛症状，在第2天显著缓解嗅觉丧失症状。全球评估显示，80.7%的患者在接受APE治疗5天后完全康复。轻度腹泻是最常见的副作用，高剂量可在几天内消退。没有与治疗相关的肝或肾毒性。
■APE在无症状或轻度患病的COVID-19患者中持续5天没有减少COVID-19的进展，然而,它缩短了嗅觉丧失的症状，在使用5天内没有副作用。
■通过前瞻性研究，与安慰剂相比，APE在无症状或轻度症状COVID-19患者中的疗效和安全性，双盲随机对照试验。患者接受含有60毫克穿心莲内酯的APE，一天三次，五天。世卫组织进展量表，COVID-19症状，和全球评估评估的疗效和不良事件，监测肝肾功能的安全性.
■165名患者完成了研究（APE组83名患者，安慰剂组82名患者）。WHO进展评分最高为4分，两组在干预的最后一天COVID-19症状均明显缓解，组间无显著差异。与安慰剂相比，APE在第1天显著缓解头痛症状，在第2天显著缓解嗅觉丧失症状。全球评估显示，80.7%的患者在接受APE治疗5天后完全康复。轻度腹泻是最常见的副作用，高剂量可在几天内消退。没有与治疗相关的肝或肾毒性。
■APE在无症状或轻度患病的COVID-19患者中持续5天没有减少COVID-19的进展，然而,它缩短了嗅觉丧失的症状，在使用5天内没有副作用。
